Omeros Corporation (NASDAQ:OMER) Stock Has Consensus Price Target of $38.00 According to Analysts

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $34.00.

A number of research analysts have commented on OMER shares. Zacks Research downgraded Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. HC Wainwright reissued a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings lowered shares of Omeros from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, September 22nd. Wall Street Zen upgraded shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Finally, Cantor Fitzgerald raised shares of Omeros from a "neutral" rating to an "overweight" rating and set a $22.00 target price for the company in a research report on Tuesday, September 22nd.

Insider Buying and Selling at Omeros

In related news, Director Thomas Cable sold 15,000 shares of the company's stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the sale, the director owned 35,067 shares of the company's stock, valued at $646,986.15. The trade was a 29.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Arnold Hanish sold 10,000 shares of the business's stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at approximately $94,750. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 105,906 shares of company stock worth $1,989,705. Insiders own 10.50% of the company's stock.

Hedge Funds Weigh In On Omeros

A number of large investors have recently modified their holdings of OMER. Assetmark Inc. acquired a new position in shares of Omeros during the first quarter worth approximately $38,000. International Assets Investment Management LLC lifted its position in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 800 shares during the period. Leonteq Securities AG acquired a new position in Omeros during the 1st quarter valued at about $106,000. Engineers Gate Manager LP bought a new position in shares of Omeros in the 2nd quarter valued at about $138,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Omeros in the 2nd quarter valued at about $146,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Price Performance

NASDAQ OMER traded down $0.05 during mid-day trading on Wednesday, hitting $19.38. The company's stock had a trading volume of 387,803 shares, compared to its average volume of 1,687,194. Omeros has a 52-week low of $4.05 and a 52-week high of $21.24. The stock's fifty day simple moving average is $16.40 and its two-hundred day simple moving average is $13.11. The firm has a market capitalization of $1.40 billion, a P/E ratio of 15.15 and a beta of 2.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, equities analysts forecast that Omeros will post -0.37 earnings per share for the current fiscal year.

Omeros Company Profile

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.